Effect of moxibustion on the expression of GDNF and its receptor GFRα3 in the colon and spinal cord of rats with irritable bowel syndrome

Qin Qi¹, Huangan Wu², Xiaoming Jin³, Duiyin Jin¹, Yuanyuan Wang¹, Cun Wang¹, Yanan Liu¹ and Xiaomei Wang¹,²

Abstract

Background: Moxibustion treatment has been found to ameliorate clinical symptoms including abdominal pain, diarrhea and constipation in patients with irritable bowel syndrome (IBS). Herein we investigated the mechanisms underlying the use of moxibustion in a rat model of IBS.

Methods: In our study, an IBS model was established in rats by colorectal distension (CRD) stimulus and mustard oil enema. The rats were randomly divided into a normal group, model group, mild moxibustion group, electroacupuncture group, probiotic group and dicetel group. Abdominal withdrawal reflex (AWR) scores were determined within 90 min of the last treatment. The expression of GDNF/GFRα3 protein and mRNA in the colon and spinal cord were detected by immunohistochemistry and quantitative real-time-PCR, respectively.

Results: The IBS model rats had significantly higher AWR scores than the normal group (P<0.01). After mild moxibustion treatment, the AWR score was significantly reduced (20 mm Hg, P<0.05; 40 mm Hg, 60 mm Hg and 80 mm Hg, P<0.01). The model group showed significantly more colonic glial cell line-derived neurotrophic factor (GDNF/GFRα3 (GDNF family receptor α3) protein and mRNA expression in the colon and spinal cord than the normal group (P<0.01). Compared with the model group, the expression of GDNF/GFRα3 protein and mRNA in the colon and spinal cord of the rats were significantly decreased in the mild moxibustion group (colon: GDNF and GFRα3 protein, P<0.01; GDNF and GFRα3 mRNA, P<0.01; spinal cord: GDNF and GFRα3 protein, P<0.01; GDNF mRNA, P<0.05, GFRα3 mRNA, P<0.01).

Conclusions: Our data suggest that moxibustion therapy may mitigate CRD-induced increases in the expression of GDNF and its receptor GFRα3 in the colon and spinal cord in a rat model of IBS.

Keywords

electroacupuncture, gastroenterology, moxibustion, irritable bowel syndrome, glial cell line-derived neurotrophic factor

Accepted: 26 February 2018

Introduction

Irritable bowel syndrome (IBS) is a common chronic functional bowel disease. Its main features include abdominal pain, changes in defecation, abnormal stool and a lack of significant organic changes. An epidemiological study has shown the global prevalence of IBS to be 11.2%.¹ Current therapeutic methods mainly include medicinal, psychological and dietary therapy.² However, medicinal therapy is limited to symptomatic treatment and is associated with certain side effects. Furthermore, the long-term effects are unsatisfactory. Acupuncture has been used as a safe and...
effective therapy to treat IBS and related functional bowel disorders.\textsuperscript{3,4} It not only mitigates clinical symptoms, including abdominal pain, diarrhea, and constipation, but also regulates intestinal substance P, vasoactive intestinal peptides and expression of the P2x7 receptor.\textsuperscript{5,6} 

The pathogenesis of IBS has not been fully characterised. Recent studies indicate that it might be associated with brain-gut interactions, visceral hypersensitivity, colonic dysmotility, and genetic and psychological factors.\textsuperscript{7,8} In recent years, studies have indicated that visceral hypersensitivity is the main cause of abdominal pain and diarrhea in patients with IBS.\textsuperscript{9} Reducing visceral hypersensitivity and relieving clinical symptoms in IBS patients are important therapeutic strategies. Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor with several biological activities. Studies have shown that the visceral hypersensitivity rat model has a high expression of GDNF.\textsuperscript{10} Tanaka et al. found a high expression of GDNF in the dorsal root ganglia of the visceral hypersensitivity rat model.\textsuperscript{11} Moxibustion is an effective method for treating IBS.\textsuperscript{12,13} In this study, we focused on visceral hypersensitivity and GDNF/GFRα3 (GDNF family receptor α3) to investigate the mechanism of action underlying the effects of moxibustion on IBS.

**Methods**

**Animals**

Sixty male Sprague-Dawley rat pups were obtained 8 days after birth from the Experimental Animal Center, Shanghai University of Traditional Chinese Medicine. The laboratory temperature was 22±2°C and humidity was 60±5%. All experimental procedures were performed according to the protocols approved by the University Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (IACUC protocol no. SYXK (Shanghai) 2009–0082) and in accordance with the National Institutes for Health (NIH) ‘Guide for the Care and Use of Laboratory Animals’ to reduce pain and to avoid harm.

**Model establishment**

The number of rats was based on the power calculation of a previous study.\textsuperscript{14} According to a random number table generated by SPSS version 21.0, 10 rats were selected as a normal group. According to the protocol described by Al-Chaer et al.,\textsuperscript{15} the remaining 50 rats formed the model group and received colorectal distension (CRD) via balloon stimulation, which is one of the most widely used methods to induce visceral hypersensitivity,\textsuperscript{16} on a daily basis between the age of 8 and 21 days. A 3 cm balloon stimulator was connected to a 10 cm long latex tube. At the end of the tube, a Y connector was attached to a syringe and sphygmonanometer, which provided constant dilation pressure and stimulation. The balloon stimulator was first lubricated with petrolatum and inserted into the rat colon in line with its physiological curvature. The balloon was inserted 2 cm deep to the anus and then inflated with 0.5 mL air for 1 min; this was repeated after 1 hour and again once a day for 14 consecutive days. After the daily procedure was finished, the rats were put back into the cages with their mothers. After 4 weeks rest, the model rats then received colonic injections of 0.2 mL 4% mustard oil once a day for 14 consecutive days. The abdominal withdrawal reflex (AWR) was tested by different observers. The model was considered successfully established when the AWR score in model rats was significantly greater than that of the normal rats.

**Grouping and processing**

The rats were randomly divided into the following groups: Normal group (NG) and Model (CRD) groups: No treatment. Mild moxibustion group (CRD+MM): Mild moxibustion (MM) was applied at bilateral ST25 (Tianshu) and ST37 (Shangjuxu). Special fine moxa sticks used for this experiment were 4 mm in diameter and 12 cm in length, and were provided by the Nanyang Hanyi Moxa factory in China. The moxibustion was performed 2–3 cm above the traditional acupuncture points for 10 min, once a day for 7 days. Electroacupuncture group (CRD+EA): Sterilised stainless steel acupuncture needles (Yunlong, Wujiang Yunlong Medical Instruments Factory, Wujiang, China) 25 mm in length and 0.3 mm in diameter were inserted to a depth of about 2–3 mm at ST25 and ST37 bilaterally. An electrical acupuncture point stimulator (HAN-200A, Jisheng Ltd, Beijing, China) was used to stimulate the needles using dilational waves (2–100 Hz, intensity 1mA). Each treatment was performed for 20 min once per day for 7 days in total. Probiotic group (CRD+PB): Bifidobacteria Triple Viable (SFDA approval no. S19980004) was administrated via oral gavage. Daily dosage was calculated according to the ratio between adult humans (70 kg body weight) and rats (200 g body weight), which was 1:0.018 (based on the Methods for Pharmaceutical Experiment). The treatment was performed once a day for 7 days in total. Dicetel group (CRD+DG): Dicetel (SFDA approval no. H20120127) was administrated via oral gavage. The same dosing and timing as the Probiotic group were applied. One rat died during the preparation of the model, two rats in the CRD+PB group and two rats in the CRD+DG group died after gavage, and three rats died for unknown reasons. The final number of rats in each group were: NG, n=8; CRD, n=8; CRD+MM, n=8; CRD+EA, n=8; CRD+PB, n=6; and CRD+DG, n=7.

**Sample collection and processing**

After treatment, all rats were weighed and anaesthetised with 2% pentobarbital sodium (2 ml/kg), and then euthanased by cervical dislocation. Spinal cords (L6–S2) and colonic samples (2–3 cm) from the distal colon were...
collected immediately. The samples were stored at −80°C for immunohistochemistry and real-time PCR analysis.

**AWR scoring**

Within 90 min of the last treatment, the AWR score was calculated according to Al-Chaer et al. Balloon dilation pressures had four pressure grades: 20, 40, 60 and 80 mm Hg. Each distension stimulation lasted about 20 s and was repeated three times. The average of the scores for each rat was used for statistical analysis. The AWR scoring standards applied were as follows: no reaction to the colorectal balloon dilation stimulation, score 0; a motion stop and a brief head movement, score 1; abdominal muscle contraction but without abdominal lifting, score 2; abdominal lifting and lifting off the platform, score 3; arching of body and lifting of pelvis and scrotum, score 4.

**Immunohistochemical analysis of GDNF and its receptor GFRα3**

Formalin-fixed paraffin-embedded sections (4 μm thick) were immunostained using anti-GDNF (ab18956, 1:100, Abcam) and anti-GFRα3 (ab8028, 1:100, Abcam) antibodies according to the manufacturer’s instructions. The primary antibodies were added and incubated at 4°C overnight, and the corresponding secondary antibodies (BA1003, 1:150, Wuhan Boster Biological Technology Co Ltd) were added and incubated at room temperature for 1 hour. After DAB reaction for 3–5 min, the sections underwent 2 min of haematoxylin staining and were then viewed under an optical microscope.

Using Image-Plus Pro image analysis software, three randomly selected sections were counted from each rat per group and analysed for the average optical density of the positive target.

**Real-time quantitative PCR analysis of GDNF and its receptor GFRα3**

Total RNA was extracted using TRIzol LS (Invitrogen Corp) according to the manufacturer’s instructions. The PCR reaction mixture (16 μL) comprised 5 μL of H2O, 8 μL of 2×SYBR Green PCR mix, 1 μL of upstream primer (10 pm/μL), 1 μL of downstream primer (10 pm/μL) and 1 μL of reverse transcription product (cDNA). Reaction conditions were as follows: 95°C for 2 min, 94°C for 10 s, 60°C for 10 s and 72°C for 40 s, 40 cycles. The sequences of the target genes were set according to the Gene Bank database. Primers were designed using ABI Primer Express Software v 2.0 and synthesised by BGI Inc. The primer sequences were as follows:

- **GAPDH:** upstream 5′-GGCAAGTTCACAACGGCAGTC-3′; downstream 5′-ATGACATCTCAGCACCAGGC-3′.
- **GDNF:** upstream 5′-TCGAAGAGAGAGGAACCCG-3′; downstream 5′-TTAGACTCCAGCACCAGGC-3′.
- **GFRα3:** upstream 5′-AAAATGCGAGGCTAATCCCG-3′; downstream 5′-ATGACATACTCAGCACCGGC-3′.

Relative mRNA expression of the target genes was calculated using the 2−ΔΔCt method: target gene ΔCt = target gene Ct − reference (GAPDH) Ct, ΔΔCt = target gene Ct − average of blank ΔCt.

**Statistical analysis**

Statistical analysis was performed using SPSS 21.0 (IBM Co, Armonk, NY, USA). Data were expressed as mean±SD (̅ x ± s ) for normal distribution and analysed using one-way analysis of variance (ANOVA). When the variance was homogeneous, the least significant difference (LSD) was used; otherwise, the Games-Howell method was used. Data were expressed as median (range) for non-normally distributed data and analysed using the rank-sum test. Differences were considered statistically significant when P<0.05.

**Results**

**AWR score**

The average stimulation score of the CRD group was significantly higher than that of the normal group (P<0.01). The various treated groups showed lower AWR scores than the CRD group in response to different stimulation intensities. Among them, the AWR scores of the CRD+MM group were significantly reduced (20 mm Hg, P<0.05; 40, 60 and 80 mm Hg, P<0.01); AWR scores of the CRD+MM group under 60 and 80 mm Hg were significantly lower than in the CRD+PB and CRD+DG groups (CRD+PB group: 60 mm Hg, P<0.05, 80 mm Hg, P<0.01; CRD+DG group: 60 mm Hg, P<0.01, 80 mm Hg, P<0.05) (Figure 1).

**Protein expression of GDNF and GFRα3 in the colon**

The CRD group showed significantly more colonic GDNF and GFRα3 protein expression than the normal group (P<0.01). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups all showed significantly less GDNF protein expression than the CRD group (CRD+MM, CRD+EA and CRD+DG groups, P<0.01; CRD+PB group, P<0.05). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups also showed significantly less GFRα3 protein expression than the CRD group (P<0.01). Compared with the CRD+MM group, protein expression of GFRα3 was higher in the CRD+PB and CRD+DG groups (P<0.01) (Figure 2).

**Protein expression of GDNF and GFRα3 in the spinal cord**

The CRD group showed significantly more GDNF and GFRα3 protein expression than the normal group (P<0.01). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups all showed significantly less GDNF and GFRα3 protein expression than the CRD group (P<0.01) (Figure 3).
mRNA expression of GDNF and GFRα3 in the colon

Compared with the normal group, the CRD group showed a significant increase in colonic GDNF and GFRα3 mRNA expression ($P<0.01$). Compared with the CRD group, the CRD+MM, CRD+EA, CRD+PB and CRD+DG groups all showed a significant decrease in colonic GDNF mRNA expression ($P<0.01$). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups also showed a significant decrease in colonic GFRα3 mRNA expression (CRD+MM group, $P<0.05$; CRD+PB, CRD+EA and CRD+DG groups, $P<0.01$). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups also showed significantly less GFRα3 mRNA expression than the CRD group ($P<0.01$) (Figure 5).

mRNA expression of GDNF and GFRα3 in the spinal cord

The CRD group showed significantly more GDNF and GFRα3 mRNA expression in the spinal cord than the normal group ($P<0.01$). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups all showed a significant decrease in GDNF mRNA expression in spinal cord (CRD+MM group, $P<0.05$; CRD+PB, CRD+EA and CRD+DG groups, $P<0.01$). The CRD+MM, CRD+EA, CRD+PB and CRD+DG groups also showed significantly less GFRα3 mRNA expression than the CRD group ($P<0.01$) (Figure 5).

Discussion

In our experiments, the AWR score was adopted to evaluate intestinal sensitivity. We found that the AWR score in the CRD group was significantly higher than in the normal group, indicating that visceral hypersensitivity in IBS rats plays an important role in the pathogenesis of the condition, which is consistent with previous findings. Visceral hyperalgesia may be the result of a combination of peripheral and central sensitisation mechanisms. The enteric nervous system (ENS), spinal cord and central nervous system (CNS) are involved in the occurrence of visceral sensation. Studies have demonstrated that the ENS contributes to visceral hypersensitivity. Therefore, it is likely that GDNF in the ENS is also involved in the formation of visceral sensitivity.
hypersensitivity. In view of this, we observed the expression of GDNF and its receptor GFRα3 in the colon and spinal cord. Studies have shown that acupuncture and moxibustion can regulate gastrointestinal function and relieve visceral hyperalgesia, and exert their therapeutic effect mainly by regulating, abnormally expressed 5-HT, TRPV1 and HSP70. In this study, AWR score was significantly decreased in the CRD+MM, CRD+EA, CRD+PB and CRD+DG groups compared with the CRD group, indicating that moxibustion can effectively alleviate visceral hypersensitivity in IBS rats as well as probiotics and dicetel. Under 60 and 80 mm Hg, the AWR score in the CRD+MM group was significantly lower than the CRD+PB and CRD+DG groups, indicating that moxibustion may be more beneficial at reducing IBS rat visceral pain. Recent studies have shown that electroacupuncture, probiotic and dicetel have good effects in the treatment of IBS. Our results suggest that moxibustion may potentially be used as an alternative treatment to probiotics and dicetel.

Figure 2. Representative immunohistochemistry images taken at ×400 magnification and mean integral optical density (IOD) in the colon (A: GDNF; B: GFRα3). Normal group: NG, n = 8; Model group: CRD, n = 8; Mild moxibustion group: CRD+MM, n = 8; Electroacupuncture group: CRD+EA, n = 8; Probiotic group: CRD+PB, n = 6; Dicetel group: CRD+DG, n = 7. Results are IOD of three visual fields per rat per group (mean ± SD). Arrows indicate positive expression of GDNF or GFRα3. *P < 0.01 versus NG; P < 0.05, P < 0.01 versus CRD; #P < 0.05, ■P < 0.01 versus CRD+MM.
GDNF can be used to treat diseases of the CNS such as Alzheimer’s disease and Parkinson’s disease.\textsuperscript{24,25} In this way, GDNF and its receptor GFR\(\alpha_3\) are critical to maintaining the CNS and ENS. Therefore, GDNF and GFR\(\alpha_3\) are likely to play a role in intestinal inflammation. Our study has shown that the expression of GDNF and GFR\(\alpha_3\) in the colon of the IBS model rats were higher than in the normal group. It is implicated that the need of neurons and glial cells for GDNF and GFR\(\alpha_3\) was increased, suggesting that GDNF and GFR\(\alpha_3\) play a protective and promotional role in the regeneration of enteric neurons, are involved in the regulation of intestinal inflammatory processes, and may have a role in promoting recovery of the intestinal mucosa in IBS.

In this study, we also found that, compared with the rats in the normal group, the expression of GDNF and GFR\(\alpha_3\) in the spinal cord of rats in the CRD group was increased. Similar to the results reported here, previous studies have also indicated that GDNF is upregulated in IBS patients.\textsuperscript{26}
Compared with the CRD group, the CRD+MM group showed a reduced expression of GDNF and GFRα3 in the colon and spinal cord. This suggests that moxibustion therapy may regulate the increased expression of GDNF and GFRα3 in the colon and spinal cord of IBS rats. Studies have shown that moxibustion can regulate intestinal inflammation to treat inflammatory bowel disease. Based on the results of our study, it is possible that moxibustion causes the enteric glial cells to secrete GDNF by regulating intestinal inflammation. Consequently, it may alleviate visceral hypersensitivity, reduce the pain threshold and relieve visceral pain. However, the exact mechanism requires further study.

**Acknowledgements**

The authors would like to thank the Experimental Animal Center, Shanghai University of Traditional Chinese Medicine for providing the animals.

**Contributors**

XW conceived and designed the study. YW and DJ performed the animal experiments and immunohistochemical analysis. CW and YL performed the PCR experiments and statistical analyses. HW and XJ prepared the Figures. XW and QQ drafted the main manuscript text. All authors revised the manuscript and approved the final version accepted for publication.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Natural Science Foundation of Shanghai (grant no. 14ZR1438700) and National Basic Research Programme of China 973 programme (grant no. 2015CB554501).

Patient consent
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

References
1. Lovell RM and Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–721.
2. Hsu HH, Leung WH, Hu GC and Ge H. Treatment of irritable bowel syndrome with a novel colonial irrigation system: a pilot study. Tech Coloproctol 2016; 20: 551–557.
3. Zhou CL, Zhao JM, Wu LY, et al. Mild moxibustion decreases the expression of prokineticin 2 and prokineticin receptor 2 in the colon and spinal cord of rats with irritable bowel syndrome. Evid Based Complement Alternat Med 2014; 2014: 807308.
4. Zhou SL, Zhang XL and Wang JH. Comparison of electroacupuncture and medical treatment for functional constipation: a systematic review and meta-analysis. Acupunct Med 2017; 35: 324–371.
5. Lu ZZ, Yin XJ, Teng WJ, et al. Comparative effect of electroacupuncture and moxibustion on the expression of substance P and vasoactive intestinal peptide in patients with irritable bowel syndrome. J Tradit Chin Med 2015; 35: 402–410.
6. Liu S, Shi Q, Zhu Q, et al. P2X7 receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia. Purinergic Signal 2015; 11: 161–169.
7. Ek WE, Reznichenko A, Ripke S, et al. Exploring the genetics of visceral hypersensitivity in irritable bowel syndrome: a GWA study in multinational case-control cohorts. Gut 2015; 64: 1774–1782.
8. Farzaei MH, Bahramsoaltani R, Abdollahi M, et al. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil 2016; 22: 558–574.
9. Ceuleers H, Van Spaendonk H, Hanning N, et al. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: the role of proteases. World J Gastroenterol 2016; 22: 10275–10286.
10. Sun Y and Sun XN. The expression of glial cell line-derived neurotrophic factor in rat model of irritable bowel syndrome. Journal of Hainan Medical College 2010; 16: 1396–1399.
11. Tanaka T, Shinoda M, Fong B, et al. Modulation of visceral hypersensitivity by glial cell line-derived neurotrophic factor family receptor &alpha;-3 in colorectal afferents. Am J Physiol Gastrointest Liver Physiol 2011; 300: G418–G424.
12. Zhao JM, Chen L, Zhou CL, et al. Comparison of electroacupuncture and moxibustion for relieving visceral hypersensitivity in rats with constipation-predominant irritable bowel syndrome. Evid Based Complement Alternat Med 2016; 2016: 9410505.
13. Wang LD, Zhao JM, Huang RJ, et al. Study on the mechanism underlying the regulation of the NMDA receptor pathway in spinal dorsal horns of visceral hypersensitivity rats by moxibustion. Evid Based Complement Alternat Med 2016; 2016: 3174608.
14. Zhang L, Liu J, Cheng C, et al. The neuroprotective effect of pyrrolquinoline quinone on traumatic brain injury. J Neurotrauma 2012; 29: 851–864.
15. Al-Chaer ED, Kawasaki M and Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000; 119: 1276–1285.
16. Moloney RD, O’Mahony SM, Dinan TG, et al. Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry 2015; 6: 15.
17. Wang ZJ, Wu LY, Zhou CL, et al. Effect of electroacupuncture on P2X3 receptor regulation in the peripheral and central nervous systems of rats with visceral pain caused by irritable bowel syndrome. Purinergic Signal 2015; 11: 321–339.
18. Ratanasrirawoot S and Irsasena N. Stem cells in the intestine: possible roles in pathogenesis of irritable bowel syndrome. J Neurogastroenterol Motil 2016; 22: 367–382.
19. Zhu X, Liu Z, Qu H, et al. The effect and mechanism of electroacupuncture at LI11 and ST37 on constipation in a rat model. Acupunct Med 2016; 34: 194–200.
20. Zou W, Lin H, Liu W, et al. Moxibustion relieves visceral hyperalgesia via inhibition of transient receptor potential vanilloid 1 (TRPV1) and heat shock protein (HSP) 70 expression in rat bone marrow cells. Acupunct Med 2016; 34: 114–119.
21. Shi Y, Chen YH, Yin XJ, et al. Electroacupuncture versus moxibustion for irritable bowel syndrome: a randomized, parallel-controlled trial. Evid Based Complement Alternat Med 2015; 2015: 361786.
22. Cui SS and Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med 2012; 5: 238–244.
23. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with irritable bowel syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Invest 2014; 34: 783–793.
24. Revilla S, Ursulet S, Álvarez-López MJ, et al. Lenti-GDNF gene therapy protects against Alzheimer’s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 2014; 20: 961–72.
25. Liu Y, Zeng X, Hui Y, et al. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease. Neuropharmacology 2015; 91: 87–96.
26. Steinkamp M, Geerling I, Seufferlein T, et al. Glial-derived neurotrophic factor regulates apoptosis in colonic epithelial cells. Gastroenterology 2003; 124: 1748–1757.
27. Huang Y, Ma Z, Cui YH, et al. Effects of herb-partitioned moxibustion on the miRNA expression profiles in colon from rats with DSS-induced ulcerative colitis. Evid Based Complement Alternat Med 2017; 2017: 1767301.